PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1656952-4 1991 Treatment with phorbol 12-myristate 13-acetate (PMA) for 24 h dose-dependently inhibited Epo formation, thus suggesting that down-regulation of PKC might be responsible for this inhibition. Tetradecanoylphorbol Acetate 15-46 erythropoietin Homo sapiens 89-92 10397715-7 1999 After cotransfection with human wild-type c-mpl, the cells (UT-7/EPO-MPL) responded to phorbol 12-myristate 13-acetate (PMA), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) with enhanced PAI-1 mRNA expression within 24 to 48 hours. Tetradecanoylphorbol Acetate 87-118 erythropoietin Homo sapiens 65-68 9419420-7 1997 Treatment with Epo or 12-O-tetradecanoyl-phorbol-13-acetate (TPA) up-regulated expression of GATA-2 and Bcl-xL, and these elevations were inhibited by inhibitors of protein kinase C (PKC), H7 and H8. Tetradecanoylphorbol Acetate 61-64 erythropoietin Homo sapiens 15-18 7679999-2 1993 The addition of phorbol 12-myristate 13-acetate (PMA) to Hep 3B cells subsequently grown under hypoxic conditions resulted in a dose-dependent inhibition of hypoxia-induced Epo production by as much as 95 +/- 1% with half-maximal inhibition at 8 ng/mL. Tetradecanoylphorbol Acetate 16-47 erythropoietin Homo sapiens 173-176 7679999-2 1993 The addition of phorbol 12-myristate 13-acetate (PMA) to Hep 3B cells subsequently grown under hypoxic conditions resulted in a dose-dependent inhibition of hypoxia-induced Epo production by as much as 95 +/- 1% with half-maximal inhibition at 8 ng/mL. Tetradecanoylphorbol Acetate 49-52 erythropoietin Homo sapiens 173-176 7679999-3 1993 By Northern blot analysis, Epo mRNA levels were correspondingly decreased after treatment with PMA. Tetradecanoylphorbol Acetate 95-98 erythropoietin Homo sapiens 27-30 7679999-6 1993 The PMA-induced inhibition of hypoxia-induced Epo production was shown to occur as early as 3 hours after PMA addition, suggesting that the initial activation, rather than the subsequent decrease in protein kinase C activity, is of primary importance. Tetradecanoylphorbol Acetate 4-7 erythropoietin Homo sapiens 46-49 7679999-6 1993 The PMA-induced inhibition of hypoxia-induced Epo production was shown to occur as early as 3 hours after PMA addition, suggesting that the initial activation, rather than the subsequent decrease in protein kinase C activity, is of primary importance. Tetradecanoylphorbol Acetate 106-109 erythropoietin Homo sapiens 46-49 7679999-7 1993 The relative specificity of the PMA-induced inhibition of Epo production was demonstrated by 1) the finding that overall protein and RNA synthesis were not similarly decreased as measured by 3H-leucine and 3H-uridine pulse labeling studies and 2) the observation that the biologically inactive phorbol ester, 4 alpha-phorbol didecanoate, failed to have any effect on hypoxia-induced Epo production. Tetradecanoylphorbol Acetate 32-35 erythropoietin Homo sapiens 58-61 7679999-7 1993 The relative specificity of the PMA-induced inhibition of Epo production was demonstrated by 1) the finding that overall protein and RNA synthesis were not similarly decreased as measured by 3H-leucine and 3H-uridine pulse labeling studies and 2) the observation that the biologically inactive phorbol ester, 4 alpha-phorbol didecanoate, failed to have any effect on hypoxia-induced Epo production. Tetradecanoylphorbol Acetate 32-35 erythropoietin Homo sapiens 383-386 1317101-3 1992 The phorbol ester phorbol 12-myristate-13 acetate (PMA) led to a concentration-dependent inhibition of basal and stimulated EPO formation (ED50 10 nM). Tetradecanoylphorbol Acetate 18-49 erythropoietin Homo sapiens 124-127 1317101-3 1992 The phorbol ester phorbol 12-myristate-13 acetate (PMA) led to a concentration-dependent inhibition of basal and stimulated EPO formation (ED50 10 nM). Tetradecanoylphorbol Acetate 51-54 erythropoietin Homo sapiens 124-127 1317101-4 1992 This decrease of EPO production, which was apparent already after 1 h of incubation with PMA, reached its maximal effect after 24 h and held on for 72 h. It was paralleled by an inhibition of the increase of EPO mRNA levels in response to stimulation. Tetradecanoylphorbol Acetate 89-92 erythropoietin Homo sapiens 17-20 1317101-4 1992 This decrease of EPO production, which was apparent already after 1 h of incubation with PMA, reached its maximal effect after 24 h and held on for 72 h. It was paralleled by an inhibition of the increase of EPO mRNA levels in response to stimulation. Tetradecanoylphorbol Acetate 89-92 erythropoietin Homo sapiens 208-211 1317101-6 1992 Recovery of EPO synthesis after removal of PMA took 48-72 h. The effect of PMA on EPO production was mimicked by phorbol 12,13-dibutyrate (ED50 1 microM) but not by 4 alpha-phorbol 12,13-didecanoate. Tetradecanoylphorbol Acetate 43-46 erythropoietin Homo sapiens 82-85 1317101-6 1992 Recovery of EPO synthesis after removal of PMA took 48-72 h. The effect of PMA on EPO production was mimicked by phorbol 12,13-dibutyrate (ED50 1 microM) but not by 4 alpha-phorbol 12,13-didecanoate. Tetradecanoylphorbol Acetate 75-78 erythropoietin Homo sapiens 12-15 1317101-6 1992 Recovery of EPO synthesis after removal of PMA took 48-72 h. The effect of PMA on EPO production was mimicked by phorbol 12,13-dibutyrate (ED50 1 microM) but not by 4 alpha-phorbol 12,13-didecanoate. Tetradecanoylphorbol Acetate 75-78 erythropoietin Homo sapiens 82-85 1656952-4 1991 Treatment with phorbol 12-myristate 13-acetate (PMA) for 24 h dose-dependently inhibited Epo formation, thus suggesting that down-regulation of PKC might be responsible for this inhibition. Tetradecanoylphorbol Acetate 48-51 erythropoietin Homo sapiens 89-92 33521906-12 2021 Two of these studies related the adverse events to the co-administration of EPO with tPA. Tetradecanoylphorbol Acetate 85-88 erythropoietin Homo sapiens 76-79 3678377-0 1987 Inhibitory effects of tetradecanoylphorbol acetate and diacylglycerol on erythropoietin production in human renal carcinoma cell cultures. Tetradecanoylphorbol Acetate 22-50 erythropoietin Homo sapiens 73-87